Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines.

In the current study, the potential blocking ability of K+ channels encoded by the human ether-a-go-go related gene (HERG) by the piperazine H1 receptor antagonist cetirizine has been examined and compared with that of other second-generation antihistamines (astemizole, terfenadine, and loratadine). Cetirizine was completely devoid of any inhibitory action on HERG K+ channels heterologously expressed in Xenopus laevis oocytes in concentrations up to 30 microM. On the other hand, terfenadine and astemizole effectively blocked HERG K+ channels with nanomolar affinities (the estimated IC50 values were 330 and 480 nM, respectively), whereas loratadine was approximately 300-fold less potent (IC50 approximately 100 microM). In addition, in contrast to terfenadine, cetirizine did not show use-dependent blockade. In SH-SY5Y cells, a human neuroblastoma clone that constitutively expresses K+ currents carried by HERG channels (IHERG), as well as in human embryonic kidney 293 cells stably transfected with HERG cDNA, extracellular perfusion with 3 microM cetirizine did not exert any inhibitory action on IHERG. Astemizole (3 microM), on the other hand, was highly effective. Terfenadine (3 microM) caused a marked (approximately 80%) inhibition of IHERG in SH-SY5Y cells, whereas loratadine, at the same concentration, caused a 40% blockade. Furthermore, the application of cetirizine (3 microM) on the intracellular side of the membrane of HERG-transfected human embryonic kidney 293 cells did not affect IHERG, whereas the same intracellular concentration of astemizole caused a complete block. The results of the current study suggest that second-generation antihistamines display marked differences in their ability to block HERG K+ channels. Cetirizine in particular, which possesses more polar and smaller substituent groups attached to the tertiary amine compared with other antihistamines, lacks HERG-blocking properties, possibly explaining the absence of torsade de pointes ventricular arrhythmias associated with its therapeutical use.

[1]  L. Bianchi,et al.  herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? , 1998, Cancer research.

[2]  C. January,et al.  Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.

[3]  M. Q. Zhang,et al.  Chemistry Underlying the Cardiotoxicity of Antihistamines , 1997 .

[4]  N. Copeland,et al.  Two isoforms of the mouse ether-a-go-go-related gene coassemble to form channels with properties similar to the rapidly activating component of the cardiac delayed rectifier K+ current. , 1997, Circulation research.

[5]  A. E. Lacerda,et al.  Interactions of the nonsedating antihistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. , 1997, Molecular pharmacology.

[6]  M. Lindquist,et al.  Dangers of non-sedating antihistamines , 1997, The Lancet.

[7]  G. Gintant,et al.  Tissue and species distribution of mRNA for the IKr-like K+ channel, erg. , 1997, Circulation research.

[8]  M. Morad,et al.  Suppression of Mammalian K 1 Channel Family by Ebastine 1 , 1997 .

[9]  A. Brown,et al.  Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.

[10]  A. Brown,et al.  HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. , 1996, Circulation.

[11]  F. Lang,et al.  Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole , 1996, FEBS letters.

[12]  M. Sanguinetti,et al.  Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. , 1996, Circulation research.

[13]  R. Egan,et al.  Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. , 1996, Arzneimittel-Forschung.

[14]  R. Woosley,et al.  Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.

[15]  L. Bianchi,et al.  A novel inward‐rectifying K+ current with a cell‐cycle dependence governs the resting potential of mammalian neuroblastoma cells. , 1995, The Journal of physiology.

[16]  M. Cayen,et al.  Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations , 1995, Clinical pharmacology and therapeutics.

[17]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[18]  R. Egan,et al.  Loratadine produces antihistamine activity without adverse CNS, ECG or cardiovascular effects in guinea pigs. Comparative studies with terfenadine and sedating antihistamines. , 1995, International archives of allergy and immunology.

[19]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[20]  C. Berul,et al.  Regulation of potassium channels by nonsedating antihistamines. , 1995, Circulation.

[21]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[22]  J. Lynch,et al.  Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.

[23]  W. Crumb,et al.  Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. , 1995, Molecular pharmacology.

[24]  J. Spertus,et al.  Monitoring the quality of life in patients with coronary artery disease. , 1994, The American journal of cardiology.

[25]  D. Peters,et al.  Loratadine , 1994, Drugs.

[26]  R. Woosley,et al.  The electrocardiographic effects of cetirizine in normal subjects , 1994, Clinical pharmacology and therapeutics.

[27]  R. Woosley,et al.  Analysis of potential adverse drug reactions--a case of mistaken identity. , 1994, The American journal of cardiology.

[28]  P. Schad,et al.  Loratadine and ventricular tachycardia. , 1994, The American journal of cardiology.

[29]  J. Warmke,et al.  A family of potassium channel genes related to eag in Drosophila and mammals. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  A. Brown,et al.  Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. , 1993, Molecular pharmacology.

[31]  B. Singh,et al.  Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. , 1993, European heart journal.

[32]  F. Guengerich,et al.  Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[33]  K. Kouvalainen,et al.  Accidental astemizole overdose in young children , 1991, The Lancet.

[34]  A. A. Mcleod,et al.  Torsades de pointes complicating treatment with terodiline. , 1991, BMJ.

[35]  C. L. Ferguson,et al.  Torsades de pointes occurring in association with terfenadine use. , 1990, JAMA.

[36]  V. Harindra,et al.  Cardiotoxic effect with convulsions in terfenadine overdose. , 1989, BMJ.

[37]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[38]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[39]  T M Craft,et al.  Torsade de pointes after astemizole overdose. , 1986, British medical journal.

[40]  R. Heel,et al.  Terfenadine. A review of its pharmacodynamic properties and therapeutic efficacy. , 1985, Drugs.

[41]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .